MedTrace Logo

The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer

NCT03076502 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-03-13

No results posted yet for this study

Summary

This study aims to evaluate the role of ct-DNA, PVT1 and reactive oxygen species (ROS) as biomarkers in the diagnosis, treatment and recurrence monitoring of gastrointestinal and hepatobiliary pancreatic cancer.

Conditions

  • Neoplasms, Gastrointestinal

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • The University of Queensland

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • JIAN WANG, M.D. · Department of Biliary-pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-30
Primary Completion
2019-04-30
Completion
2019-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076502 on ClinicalTrials.gov